Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2019 Mar;38(3):252-259.
doi: 10.1016/j.healun.2018.12.006. Epub 2018 Dec 14.

Azithromycin and early allograft function after lung transplantation: A randomized, controlled trial

Anke Van Herck  1 , Anna E Frick  2 , Veronique Schaevers  1 , Annelies Vranckx  3 , Eric K Verbeken  4 , Bart M Vanaudenaerde  1 , Annelore Sacreas  1 , Tobias Heigl  1 , Arne P Neyrinck  5 , Dirk Van Raemdonck  6 , Lieven J Dupont  1 , Jonas Yserbyt  1 , Stijn E Verleden  1 , Geert M Verleden  1 , Robin Vos  7
Affiliations
Randomized Controlled Trial

Azithromycin and early allograft function after lung transplantation: A randomized, controlled trial

Anke Van Herck et al. J Heart Lung Transplant. 2019 Mar.

Abstract

Background: Chronic lung allograft dysfunction (CLAD) is the single most important factor limiting long-term survival after lung transplantation (LTx). Azithromycin has been shown to improve CLAD-free and long-term survival, yet the possible impact on early lung allograft function is unclear.

Methods: A prospective, randomized, double-blind, placebo-controlled trial of pre-transplant and prompt post-transplant azithromycin treatment was performed at the University Hospitals Leuven. In each arm, 34 patients, transplanted between October 2013 and October 2015, were included for analysis. Study drug was added to standard of care and was administered once before LTx (1,000 mg of azithromycin or placebo) and every other day from Day 1 until Day 31 after LTx (250 mg of azithromycin or placebo). Primary outcome was an anticipated 15% improvement of forced expiratory volume in 1 second (FEV1, percent predicted) during the first 3 months post-LTx. Secondary end-points included length of intubation, days on ventilator, duration of intensive care unit and hospital stay, prevalence and severity of primary graft dysfunction, acute rejection, infection, and CLAD-free and overall survival.

Results: FEV1 was not significantly different between the 2 groups (p = 0.41). Patients treated with azithromycin demonstrated less airway inflammation, with lower bronchoalveolar lavage (BAL) neutrophilia and BAL interleukin-8 protein levels at Day 30 (p = 0.09 and p = 0.04, respectively) and Day 90 (p = 0.002 and p = 0.08, respectively) after LTx. Other secondary outcomes were not significantly different between placebo and azithromycin groups.

Conclusions: Pre-transplant and prompt post-transplant azithromycin treatment was not able to improve early lung allograft function. However, the known anti-inflammatory properties of azithromycin were confirmed (NCT01915082).

Keywords: azithromycin; chronic lung allograft dysfunction; early lung allograft function; lung transplantation; survival.

PubMed Disclaimer

Publication types

Associated data